MannKind (MNKD) News Today $3.46 -0.53 (-13.28%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$3.62 +0.16 (+4.48%) As of 08/6/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Why Is MannKind Dropping Today?Toggle Visibility of Why Is MannKind Dropping Today?MannKind Corporation (NASDAQ: MNKD) shares have been volatile today following the release of its Q2 2025 earnings, a significant financing deal and fresh analyst commentary. Investors are weighing mixed financial results against a new non-dilutive capital infusion and reiterated bullish outlooks. Key drivers impacting MNKD today include: Positive Sentiment: Signed a non-dilutive strategic financing agreement with Blackstone, securing up to $500 million and $75 million in cash at closing to bolster its capital structure. MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement Positive Sentiment: Wedbush analyst reiterates a Buy rating, citing clinical progress in inhaled therapeutics and the company’s strengthened financial position. Promising Outlook for MannKind: Buy Rating Justified by Clinical Progress and Financial Strength Positive Sentiment: Reported Q2 revenues of $76.5 million, up 6% year-over-year, with YTD revenues rising 12% compared to 2024. MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update Neutral Sentiment: Delivered break-even Q2 earnings per share versus the Zacks consensus estimate of $0.04, reflecting a mixed result on profitability. MannKind (MNKD) Reports Break-Even Earnings for Q2 Neutral Sentiment: Analyst firm Seeking Alpha's post-Q2 assessment highlights continued support from analysts and decent growth across its core inhaled therapies. MannKind Corporation: A Post-Q2 Assessment Negative Sentiment: Revenue of $76.53 million slightly missed consensus estimates of $77.82 million, undercutting top-line expectations. View Press Release Negative Sentiment: Shares dipped amid signs of softening demand, with analysts citing lower-than-expected uptake in its core products. MannKind (MNKD) Shares Dip on Revenue Miss and Declining Demand Negative Sentiment: Stock reacted to the headline profit and revenue miss, pulling shares lower after the Q2 report. MannKind stock falls after profit and revenue miss Posted 6h agoAI Generated. May Contain Errors. MNKD Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period MannKind Corporation Reports Q2 2025 Financial Growth2 hours ago | tipranks.comDecoding MannKind Corp (MNKD): A Strategic SWOT Insight2 hours ago | gurufocus.comQ2 2025 MannKind Corp Earnings Call Transcript3 hours ago | gurufocus.comMannKind Corporation (MNKD) Q2 2025 Earnings Conference Call TranscriptAugust 6 at 6:13 PM | seekingalpha.comMannKind Corporation: A Post-Q2 AssessmentAugust 6 at 5:36 PM | seekingalpha.comMannKind Corporation: A Post-Q2 AssessmentAugust 6 at 5:06 PM | seekingalpha.comPromising Outlook for MannKind: Buy Rating Justified by Clinical Progress and Financial StrengthAugust 6 at 1:31 PM | tipranks.comMannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business UpdateAugust 6 at 10:02 AM | gurufocus.comMannKind (MNKD) Shares Dip on Revenue Miss and Declining DemandAugust 6 at 10:01 AM | gurufocus.comMannKind stock falls after profit and revenue missAugust 6 at 9:32 AM | seekingalpha.comMannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business UpdateAugust 6 at 7:17 AM | globenewswire.comMannKind and Blackstone Announce up to $500 Million Strategic Financing AgreementAugust 6 at 7:10 AM | globenewswire.comMannKind (MNKD) Prepares to Announce Q2 EarningsAugust 5 at 1:43 PM | gurufocus.comMannKind Q2 2025 Earnings PreviewAugust 5 at 12:42 PM | seekingalpha.comMannKind (NASDAQ:MNKD) Lowered to Hold Rating by Wall Street ZenAugust 3, 2025 | marketbeat.comFederated Hermes Inc. Cuts Stock Position in MannKind Corporation (NASDAQ:MNKD)August 3, 2025 | marketbeat.comH.C. Wainwright Affirms MannKind Corp (MNKD)’s ‘Buy’ Rating Buoyed by Product PipelineAugust 1, 2025 | insidermonkey.comWedbush Remains Bullish on MannKind Corporation (MNKD)August 1, 2025 | msn.comMannKind (MNKD) Expected to Announce Quarterly Earnings on WednesdayJuly 31, 2025 | marketbeat.comMannKind Corporation to Release Second Quarter 2025 Financial Results and Host Webcast on August 6, 2025July 30, 2025 | quiverquant.comQMannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025July 30, 2025 | globenewswire.comVictory Capital Management Inc. Acquires 137,833 Shares of MannKind Corporation (NASDAQ:MNKD)July 30, 2025 | marketbeat.comRBC Capital Lowered the PT on MannKind Corporation (MNKD), Kept a Buy RatingJuly 28, 2025 | insidermonkey.comMannKind Corporation (MNKD) Presented Inhaled Insulin Therapy At American Diabetes AssociationJuly 23, 2025 | insidermonkey.comMannKind (NASDAQ:MNKD) Given New $8.00 Price Target at Royal Bank Of CanadaJuly 23, 2025 | marketbeat.comHC Wainwright Estimates MannKind FY2025 EarningsJuly 21, 2025 | marketbeat.comMannKind Corporation (NASDAQ:MNKD) Receives Average Rating of "Buy" from AnalystsJuly 19, 2025 | marketbeat.comMannKind (NASDAQ:MNKD) Upgraded at Wall Street ZenJuly 19, 2025 | marketbeat.comMannKind Corporation (NASDAQ:MNKD) Director Steven B. Binder Sells 75,367 SharesJuly 18, 2025 | marketbeat.comInsider Selling: MannKind Corporation (NASDAQ:MNKD) Director Sells 75,367 Shares of StockJuly 18, 2025 | insidertrades.comHC Wainwright Estimates MannKind's Q2 Earnings (NASDAQ:MNKD)July 18, 2025 | marketbeat.comMannKind's (MNKD) Buy Rating Reiterated at HC WainwrightJuly 16, 2025 | marketbeat.comWells Fargo Maintains a Buy Rating on MannKind Corporation (MNKD), Sets a $9 PTJuly 11, 2025 | insidermonkey.comMannKind (NASDAQ:MNKD) Hits New 52-Week Low - Here's WhyJuly 7, 2025 | marketbeat.comMannKind (NASDAQ:MNKD) Hits New 1-Year Low - What's Next?July 1, 2025 | marketbeat.comMannKind (NASDAQ:MNKD) Rating Lowered to "Hold" at Wall Street ZenJune 27, 2025 | marketbeat.comHealth Rounds: Inhaled insulin as good as injection for children at mealtimeJune 25, 2025 | reuters.comMannKind (NASDAQ:MNKD) Stock Price Down 5.6% - What's Next?June 25, 2025 | marketbeat.comLeerink Partners Slashes MannKind Corporation’s (MNKD) Price Target to $7, Keeps a Buy RatingJune 24, 2025 | insidermonkey.comMannKind Corporation (NASDAQ:MNKD) Given Average Recommendation of "Buy" by BrokeragesJune 24, 2025 | marketbeat.comMannKind FY2026 EPS Forecast Decreased by Leerink PartnrsJune 19, 2025 | marketbeat.comMannKind (NASDAQ:MNKD) Reaches New 1-Year Low - Should You Sell?June 17, 2025 | marketbeat.comMannKind’s Afrezza: A Significantly Undervalued Investment Opportunity with Promising Clinical DataJune 16, 2025 | tipranks.comMannKind (NASDAQ:MNKD) Upgraded by Wall Street Zen to "Buy" RatingJune 14, 2025 | marketbeat.comInsider Selling: MannKind Co. (NASDAQ:MNKD) Director Sells 64,085 Shares of StockJune 11, 2025 | insidertrades.comInsider Sell: Steven Binder Sells 64,085 Shares of MannKind Corp (MNKD)June 10, 2025 | gurufocus.comMannKind Co. (NASDAQ:MNKD) Director Sells 64,085 SharesJune 10, 2025 | marketbeat.comMannKind’s Strategic Growth Potential and Market Positioning: A Buy RecommendationJune 10, 2025 | tipranks.comMannKind (NASDAQ:MNKD) Sets New 1-Year Low - Time to Sell?June 10, 2025 | marketbeat.comCantor Fitzgerald Estimates MannKind FY2026 EarningsJune 10, 2025 | marketbeat.com Get MannKind News Delivered to You Automatically Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. Email Address MNKD Media Mentions By Week MNKD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MNKD News Sentiment▼0.570.42▲Average Medical News Sentiment MNKD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MNKD Articles This Week▼205▲MNKD Articles Average Week Get MannKind News Delivered to You Automatically Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alkermes News Ligand Pharmaceuticals News Amicus Therapeutics News BioCryst Pharmaceuticals News Celldex Therapeutics News Dynavax Technologies News Innoviva News Novavax News OPKO Health News Geron News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MNKD) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share MannKind With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MNKD Stock Alerts